How AI Is Changing Revenue Management in the Pharmaceutical Industry

Pharmaceutical revenue has many moving parts. A sale might involve a wholesaler, a specialty pharmacy, a payer, and several different pricing or rebate agreements. By the time the numbers reach the finance team, plenty of opportunities exist for things to change or be recorded differently along the way.

Traditionally, finance teams have handled this complexity through spreadsheets, manual checks, and regular reconciliation. While these methods are useful, they become harder to manage as transaction volumes increase and contracts become more complex.

AI offers another way to handle some of the work. Rather than asking finance teams to check everything manually, AI can analyse large amounts of data, identify unusual activity and help teams focus their attention where it’s needed most.

Why AI Is Finding A Place In Pharmaceutical Finance

Developing a new medicine is an expensive and lengthy process. Deloitte's latest analysis of the top 20 global biopharma companies found that, in 2025, the average cost of bringing a drug from discovery to launch reached $2.671 billion.

When so much money is tied up in bringing products to market, getting the commercial side right matters. Small errors in billing or pricing rarely attract attention on their own, but they multiply when teams still handle each step by hand, from setting up a contract to invoicing and collecting payment. Those errors become much less frequent once finance teams start automating the order-to-cash cycle, as contract terms carry straight into invoices rather than being re-keyed along the way.

Finance teams also have more data to manage. Contracts can include different prices, discounts, milestones, and payment conditions, while claims and adjustments may arrive weeks or months after the original transaction.

AI can process large datasets much faster than a person, making it possible to spot patterns that might otherwise go unnoticed. An IQVIA survey of senior commercial leaders found that nearly half of the organisations surveyed now allocate more than 20% of their commercial budgets to AI. The research also suggests that areas such as market access and compliance still have room for greater use of AI.

Where AI Is Transforming Revenue Management

AI won't automate every part of pharmaceutical revenue management. However, it can play a useful role in some areas.

1. Spotting Problems in Rebates And Chargebacks
Rebates and chargebacks can be hard to track because they often aren't settled at the same time as the original sale. A finance team might have thousands of claims to review, with differences between what was expected and what was eventually submitted. Checking all of these manually takes time and increases the chance of missing a relatively small discrepancy. AI can compare expected and actual claims and flag unusual differences. That lets finance staff focus on exceptions rather than reviewing every transaction the same way.
2. Making Sense of Contract Terms
Pharmaceutical contracts can contain a lot of detail. Prices may change based on volume, customers, or markets, and rebates can be calculated using different formulas. Getting these details into the right systems is important. A contract might be signed correctly but still create problems if its terms aren't reflected accurately when orders are processed and invoices generated. AI can extract information from contracts and identify key terms, making it easier to transfer relevant details into revenue management processes.
3. Finding Unusual Revenue Patterns
An AI system can compare current transactions with historical patterns and flag unusual activity. That might be an unexpected price, a missing charge, or a transaction that doesn't fit the normal pattern for a particular customer or product. This can then be investigated and, when necessary, addressed to resolve the issue quickly and efficiently.
4. Supporting Revenue Recognition
Revenue recognition becomes more complicated when pharmaceutical agreements include milestones, multiple performance obligations, or licensing arrangements.

Under ASC 606, companies need to determine when revenue should be recognised and how different parts of a contract should be treated. AI-assisted systems can help by linking contract information to revenue schedules and flagging situations that may need further review.

How AI Is Improving Visibility Across Revenue Operations

Imagine a finance team discovering at the end of a quarter that a pricing rule has been applied incorrectly across a group of transactions. The team then has to trace it back, correct it, and explain it. If the same issue is identified almost immediately after it first happens, the response can be much simpler.

AI can continuously analyse transaction and contract data to help identify changes or patterns that would be difficult to spot through periodic manual reviews. A GlobalData survey published in 2026 found that 34% of pharmaceutical professionals reported function-specific AI deployment, while a further 25% said they were running pilots. Adoption is growing, but companies are still working out where AI delivers the most practical value.

What Pharmaceutical Companies Need to Consider When Adopting AI

Putting AI into a revenue process doesn't automatically make that process better. If contract information is incomplete, customer data is inconsistent, or billing systems don't communicate properly, an AI system faces the same underlying problems. In some cases, it may reproduce those problems even faster.

Data quality therefore needs to be considered before expanding an AI project. People also need a clear role. A system flagging an unusual transaction doesn't necessarily mean that transaction is wrong. Someone still needs to investigate and decide what to do next.

This is particularly important when pricing and rebates have regulatory implications. Finance teams need to know why a system has made a particular calculation or flagged a particular transaction. They also need a clear record of what happened afterward.

The technology is still developing, and not every revenue process is ready for AI. But where there is a large volume of structured data, repeated manual work, and a clear set of rules to work from, it can offer a practical way to improve how revenue is managed.

For pharmaceutical companies, that could mean fewer surprises, quicker investigations, and a clearer view of what is happening across the revenue cycle.

References:
1.    Deloitte. (2025). Weight-loss drugs boom drives pharma R&D returns.
https://www.deloitte.com/uk/en/about/press-room/weight-loss-drugs-boom-drives-pharma-r-and-d-returns.html
2.    Revcue. Order-to-cash process automation.
https://www.recvue.com/blog/order-to-cash-process-automation/
3.    IQVIA. AI in Life Sciences Commercialization: White Paper.
https://www.iqvia.com/-/media/iqvia/pdfs/library/white-papers/ai-in-life-sciences-commercialization-white-paper.pdf
4.    KPMG. (2025). Handbook: Revenue recognition.
https://kpmg.com/us/en/frv/reference-library/2025/handbook-revenue-recognition.html
5.    GlobalData. (2026). AI integration in pharmaceutical processes remains focused on high-impact functions, says GlobalData.
https://www.globaldata.com/media/pharma/ai-integration-in-pharmaceutical-processes-remains-focused-on-high-impact-functions-says-globaldata/